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Lewis M. Slater, 2 and Jeanne E. Hendrickson 1, 3 BACKGROUND: Few therapeutic options currently exist to prevent or to mitigate transfusion-associated red blood cell (RBC) alloimmunization. We hypothesized that bortezomib, a proteasome inhibitor currently being utilized for HLA alloantibody and ADAMTS13 autoantibody reduction, may be beneficial in a transfusion setting. Herein, we utilized a reductionist murine model to test our hypothesis that bortezomib would decrease RBC alloimmune responses.
STUDY DESIGN AND METHODS:
Wild-type mice were treated with bortezomib or saline and transfused with murine RBCs expressing the human KEL glycoprotein. Levels of anti-KEL immunoglobulins in transfusion recipients were measured by flow cytometry. The impact of bortezomib treatment on recipient plasma cells (PCs) and other immune cells was also assessed by flow cytometry and immunofluorescence.
RESULTS: After bortezomib treatment, mice had a 50% reduction in splenic white blood cells and a targeted reduction in marrow PCs. Mice treated with bortezomib before the transfusion of KEL RBCs became alloimmunized in three of three experiments, although their serum anti-KEL IgG levels were 2.6-fold lower than those in untreated mice. Once a primary antibody response was established, bortezomib treatment did not prevent an anamnestic response from occurring.
CONCLUSION:
To the extent that these findings are generalizable to other RBC antigens and to humans, bortezomib monotherapy is unlikely to be of significant clinical benefit in a transfusion setting where complete prevention of alloimmunization is desirable. Given the impact on PCs, however, it remains plausible that bortezomib therapy may be beneficial for RBC alloimmunization prevention or mitigation if used in combination with other immunomodulatory therapies.
E xposure to foreign antigens on red blood cells (RBCs) through transfusion or pregnancy may lead to the generation of alloantibodies. 1 Approximately 3% to 10% of transfusion recipients become alloimmunized to RBC antigens, [2] [3] [4] and approximately 1 in every 600 pregnancies is affected by maternal RBC alloantibodies. 5, 6 In a transfusion setting, RBC alloantibodies may lead to premature clearance of transfused RBCs, hemolytic transfusion reactions, or even death. 7 In a pregnancy setting, these alloantibodies may lead to hemolytic disease of the fetus and newborn. 5, 8 To date, few therapies exist to prevent the formation of RBC alloantibodies or to mitigate the dangers of existing alloantibodies induced through transfusion. Avoidance of RBCs or antigens altogether is desirable but not often feasible, and little knowledge exists about steps that initiate a humoral immune response to these antigens. 9 In theory, immunomodulatory treatments that impact plasma cells (PCs) may decrease alloimmunization, although targeting these cells poses a significant therapeutic challenge in alloimmune and autoimmune conditions alike. Given the high rate of antibody synthesis, however, PCs are particularly sensitive to proteasome inhibition, which blocks NF-jB activation and results in the accumulation of misfolded proteins in the endoplasmic reticulum. This triggers the terminal unfolded protein response, leading to the apoptosis of PCs. 10, 11 Bortezomib, a drug that binds reversibly to the 26S proteasome, is Food and Drug Administration approved for use in multiple myeloma and mantle cell lymphoma and has been used in an off-label manner for diseases involving pathologic allo-or autoantibodies. It has increasingly been used as an adjunct therapy to mitigate HLA antibody-mediated rejection in solid organ transplantation. [12] [13] [14] [15] [16] [17] [18] It has also been recently used for refractory autoimmune hemolytic anemia, 19, 20 for refractory thrombotic thrombocytopenic purpura, [21] [22] [23] for Factor (F)VIII inhibitor eradication (in a single case involving an acquired inhibitor), 24 and for mitigation of antibody responses to enzyme replacement therapy in patients with Pompe's disease. 25 Bortezomib treatment in animal models of lupus has resulted in mitigation of the clinical symptoms and significantly decreases double-stranded DNA specific autoantibody production. 26, 27 In a chronic graft-versus-host disease setting in mice, bortezomib treatment ameliorated cutaneous lesions and decreased total germinal center (GC) B cells and B-cell activation factor gene expression. 28 However, the benefit of bortezomib, compared to that of bortezomib in combination with therapeutic plasma exchange, rituximab, and other immunomodulatory therapies, has been difficult to assess in some instances. Given the PC-focused target of bortezomib, we hypothesized that the drug would mitigate the formation of alloantibodies in a transfusion setting. We tested this hypothesis in a reductionist murine model, in which donor RBCs express the human KEL glycoprotein and in which serum anti-KEL alloantibodies can be readily measured in wild-type recipients after transfusion. 7 
MATERIALS AND METHODS

Mice
C57BL/6 mice were purchased from the National Cancer Institute or Taconic. Transgenic mice expressing the human KEL glycoprotein on the RBCs, previously published as KEL2b mice, were generated previously. 29 All procedures and protocols were approved by Yale University's Institutional Care and Use Committee. 
Bortezomib treatment and transfusion
Flow cytometry and analysis
Flow cytometric crossmatch
Anti-KEL alloantibodies in transfusion recipients were measured by flow cytometric crossmatch as previously described 31 
Immune cell analysis
Single-cell suspensions from marrow and spleen tissues at specified time points were collected. In brief, spleens were harvested and homogenized into a single-cell suspension in Hank's balanced salt solution (HBSS) using the plunger of a 5-mL syringe. Single cells from marrow tissues were obtained by pipetting in HBSS. For flow cytometric analysis of immune cells, RBCs were lysed using ammonium chloride and potassium bicarbonate salt solution. Cells were stained with antibodies in buffer containing 0.1% EDTA and 0.01% bovine serum albumin. Different immune cell subsets in splenocytes and marrow cells were analyzed via flow cytometry using fluorochromeconjugated monoclonal antibodies to mouse surface markers CD19, CD45R (B220), CD5, CD1d, CD21/35, CD23, CD25, GL7, CD95, CD138, CD3, CD4, and CD44 (BD Biosciences or eBiosciences). To detect regulatory T cells (Tregs), intracellular Foxp3 staining with a cell fixation and permeabilization kit (Fix & Perm Cell, eBiosciences) was performed according to the manufacturer's instructions. Live cells were first gated using live/dead stain (BioLegend). Samples were analyzed on a flow cytometer (LSR II, BD Biosciences) or on an analyzer (MACSQuant, Miltenyi).
Immunofluorescence
Spleens were cryopreserved in optimal cutting temperature medium, sectioned on a cryostat, and stained as described previously. 32 In brief, frozen sections of 8 mm thickness were fixed in acetone, washed in ice-cold PBS, and stained at room temperature for 60 minutes with anti-B220 (AF488) and biotinylated PNA in 5% fetal calf serum/ PBS solution. For consistency, near middle sections of the spleens were used for staining and were then analyzed using an automated wide-field microscope (Eclipse Ti, Nikon) and CCD camera (Retiga 2000R, Qimaging) with NIS elements software. The follicles present in the entire field of view of each section were analyzed.
Statistical analysis
All statistical analyses were performed using computer software (GraphPad Prism, GraphPad, Inc.). The data were analyzed using the Mann-Whitney U test (to determine significant differences between two groups), the KruskalWallis test with Dunn's posttest (to determine significant differences between multiple groups), and the Wilcoxon matched-pairs signed-rank test (to evaluate changes in paired samples). Error bars represent one standard deviation, and significance was determined by a p value of less than 0.05. 
RESULTS
Bortezomib pretreatment of recipients decreases the magnitude of but does not prevent a primary KEL IgG alloantibody response
To investigate whether the proteasome inhibitor bortezomib inhibits RBC alloantibody generation during a primary immune response, mice were treated with bortezomib before transfusion (two injections at 36-hr interval with the second injection 48 hours before transfusion) and after transfusion (one injection every 3-4 days) of transgenic KEL RBCs (Fig. 1A) . The formation of KEL-specific RBC alloantibodies in sera was assessed at multiple time points after transfusion, with no significant differences in KELspecific IgM noted between bortezomib treated or untreated mice 5 days after transfusion in three of three experiments with three to five mice per group per experiment ( Fig. 1B shows a representative experiment) . However, mice treated with bortezomib had significantly lower levels of anti-KEL IgG compared to untreated mice 28 days after transfusion in two of these experiments (p5 0.004 between groups in one experiment and p 5 0.005 between groups in a repeat experiment), with a third experiment showing a similar trend but a nonsignificant p value (p 5 0.09) between groups; Fig. 1B shows a representative experiment. Taking all three experiments together, mice treated with bortezomib had a mean 2.6-fold decrease in anti-KEL IgG levels compared to untreated mice. The generation of anti-KEL IgG subtypes was then investigated by flow cytometry, using secondary reagents specific for IgG1, IgG2b, IgG2c, and IgG3. Mice treated with bortezomib had lower levels of all IgG subtypes compared to those transfused without bortezomib treatment, although no targeted depletion of any one particular IgG subtype was observed in bortezomib-treated mice (Fig. 1C) .
Bortezomib given IV or IP decreases the absolute number of all lymphocytes and preferentially decreases PCs
To characterize the impact of bortezomib on PCs and other immune cells, mice were injected twice with bortezomib IV or IP, 36 hours apart. Recipients were euthanized 36 hours after the second injection, and different tissues were isolated for analysis ( Fig. 2A ). There was a significant reduction in the total number of lymphocytes in spleens of mice treated with bortezomib IV (p < 0.01) compared to mice that were not injected with the drug (Fig. 2B) . We observed a similar reduction in lymphocyte counts in the marrow tissues as well (data not shown), with both routes of bortezomib injection having similar effects. When we analyzed immune cell subpopulations in the spleen, namely, total CD31 T cells and CD191 B2201 B cells (Fig. 2C ), CD21/35 hi CD23 -marginal zone B cells (Fig. 2D) , CD41 Foxp31 regulatory T cells and CD51 CD1d hi regulatory B cells (Figs. 2E and 2F), we did not observe a specific reduction in their relative frequencies upon treatment with the drug. However, the frequency of B220 lo CD138 hi PCs in marrow was significantly lower in mice treated with bortezomib compared to mice that were not given the drug regardless of route (p < 0.05, Fig. 2G ), as was the frequency of PCs in the spleen (Fig. 2H , p < 0.05, IV compared to control group). Thus, consistent with previously published data, bortezomib treatment led to preferential depletion of PCs. 
Bortezomib treatment decreases recipient PC responses to transfused KEL RBCs
Having observed a significant reduction in the magnitude of KEL-specific alloantibodies in bortezomib-treated transfusion recipients, we next investigated the activation status of T cells, GC B cells, and antibody-producing PCs in the marrow 33, 34 in mice transfused in the presence or absence of bortezomib. No differences in CD41 T cell CD44 (a marker for T-cell activation) expression was noted on splenocytes on D7 or D28 after KEL RBC transfusion, in the presence or absence of bortezomib (Figs. 3A and  3B ). In contrast, we observed a trend of a decreased frequency of GC B cells on Day 7 posttransfusion in the spleens of mice transfused in the presence of bortezomib compared to those transfused in the absence of bortezomib (Figs. 3C and 3D, p < 0.01, between mice transfused in the absence of bortezomib and na€ ıve animals). Immunofluorescence showed that mice treated with bortezomib formed fewer GCs (30% of sections from six spleens had GC clusters using PNA staining) compared to mice that were not treated with bortezomib (100% of sections from six spleens had GC clusters using PNA staining); Fig. 3E shows a representative image. Additionally, the frequency of PCs in marrow on Day 28 posttransfusion was significantly increased in mice transfused in the absence of bortezomib compared to na€ ıve animals (p < 0.01), with no significant difference noted between mice transfused in the presence of bortezomib compared to na€ ıve animals (Figs. 3F and 3G).
Bortezomib treatment before primary KEL RBC exposure does not prevent an anamnestic response to secondary KEL RBC exposure
Since bortezomib treatment led to significant suppression of KEL-specific antibody production, we wondered whether treatment before an initial KEL RBC exposure may mitigate alloantibody responses to subsequent KEL RBC exposures. To this end, 9 weeks after the initial transfusion, mice that were or were not treated with bortezomib during primary KEL RBC transfusion were challenged with a secondary KEL RBC transfusion without bortezomib treatment and assessed for secondary KEL-specific alloantibody responses (Fig. 4A) . Bortezomib treatment did not prevent an anamnestic response from occurring, although the absolute signal of the secondary antibody response showed a lower trend in mice treated with bortezomib before the primary RBC exposure compared to those retransfused in the absence of bortezomib. Figure  4B shows a representative experiment, with no significant differences observed between primary and secondary responses in either group using the Wilcoxon matched- Bortezomib treatment (for the first time) before secondary antigen exposure does not prevent an anamnestic response A clinically significant question revolves around whether bortezomib may be utilized to lower alloantibody titers before emergent incompatible RBC transfusion. To investigate this question, we transfused mice with KEL RBCs and tested anti-KEL responses at the peak of the antibody response. The alloimmunized mice were then either treated with bortezomib or received no treatment during a secondary KEL RBC transfusion. KEL-specific alloantibody responses were assessed 14 days after the secondary transfusion (Fig. 5A ). There were no significant differences noted between primary and secondary anti-KEL IgG responses in mice treated or not treated with bortezomib before secondary antigen exposure using the Wilcoxon matched-pairs signed-rank test (Fig. 5B , p 5 0.125, between primary and secondary responses in both groups). Similar results were observed in a total of three experiments, with three to five mice per group per experiment.
DISCUSSION
To date, there are no pharmacologic therapies known to decrease primary RBC alloimmune responses in a transfusion setting, and few therapies exist to mitigate secondary alloimmune responses. This study, which investigated the impact of the proteasome inhibitor bortezomib on alloimmunization to the human KEL glycoprotein expressed on murine RBCs, was undertaken with the hypothesis that targeted PC reduction may prevent this complication which has implications for transfusion and pregnancy. A series of experiments, completed in a reductionist murine model, showed that although bortezomib monotherapy decreased the magnitude of a primary IgG KEL-specific RBC alloantibody response after transfusion, it did not prevent an immune response altogether. Further, bortezomib therapy was unable to prevent anamnestic anti-KEL responses altogether. The fact that bortezomib was unable to completely prevent primary or secondary IgG KEL RBC alloantibody responses is disappointing, but not entirely surprising. 35 In accordance with prior studies, bortezomib decreased but did not eliminate PCs in the marrow. Further, although splenic GC B cells were decreased quantitatively in bortezomib-treated mice transfused with transgenic KEL RBCs, this decrease was not significant. The decreased anti-KEL response was likely due principally to the effect of bortezomib on PCs, but it cannot be ruled out that the response was also due in part to bortezomib nonselectively decreasing other cell types. For example, bortezomib decreased splenic marginal zone B cells by approximately 50%, and these cells are known to play a role in responses to other blood-borne antigens. [36] [37] [38] However, the decrease in marginal zone B cells was equal to the decrease in other cells types such as CD41 T cells, regulatory T cells, and regulatory B cells. Of note, the role that these cells play in alloimmune responses to transfused KEL RBCs is not yet fully understood.
One advantage of studying the KEL reductionist RBC alloimmunization model is that the timing of initial and subsequent RBC exposure can be controlled, and the impact of bortezomib as a monotherapy can readily be studied. In contrast, many of the case reports of the use of bortezomib for the treatment of pathologic allo-or antibodies involve patients with refractory antibody-mediated diseases, previously treated with multiple immunomodulatory therapies. As such, the effect of bortezomib itself on changes in antibody titers, the complement-fixing capabilities of antibodies, 39 or documented clinical improvements has been difficult to assess. It is plausible that bortezomib in combination with B-cell depletion or other immunomodulatory therapy may more efficiently decrease RBC alloimmunization in our murine model than treatment with bortezomib alone, 13, 40 as has been shown to lead to clinical improvement in refractory thrombotic thrombocytopenic purpura patients 22 and in a single patient with an acquired FVIII inhibitor. 24 It is also plausible that combined targeting of the proteosome and the glutamate antiporter might circumvent bortezomib resistance, at least in multiple myeloma cells. 41 Notably, B-cell depletion as a monotherapy has recently been used in an attempt to prevent delayed hemolytic transfusion reactions in highly alloimmunized patients with sickle cell disease, although some patients have had breakthrough hemolysis and some have formed additional RBC alloantibodies despite rituximab therapy. [42] [43] [44] [45] The care of alloimmunized patients remains a clinical challenge, regardless of whether the sensitizing antigen is on an RBC, white blood cell, or tissue and regardless of whether the sensitizing event occurs through transfusion, pregnancy, or transplantation. Some patients have so many RBC alloantibodies that crossmatch-compatible RBCs cannot be located for transfusion; 42 others have so many HLA antibodies that compatible organs cannot be located for transplantation. We initiated these murine studies with the hope that bortezomib treatment of alloimmunized mice might eliminate anti-KEL altogether or decrease anti-KEL titers to the point that the animals could be safely transfused with antigen-positive RBCs. However, the anti-KEL IgG levels in animals treated with bortezomib were high enough to be functionally significant and capable of leading to rapid clearance of transfused-incompatible KEL RBCs. In other situations, potentially including HLA antibody-mediated solid organ transplant rejection or thrombotic thrombocytopenic purpura, reduction of an allo-or autoantibody below a certain threshold might be more clinically meaningful. Limitations to this study must be taken into consideration. We studied just one RBC antigen, selecting the KEL glycoprotein given the clinical significance of antibodies against antigens in this family in mice and in humans. However, it cannot be ruled out that different results may be observed in studies using other RBC antigens, given known structural (and functional) differences. Further, the route by which the antigen is introduced may be impactful, in considering differences between immune responses to antigens on transfused RBCs and solid organs, for example. It should also be considered that humans may respond subtly differently to bortezomib compared to mice, although similar toxicities have been noted. Finally, the primary measure of immunity described in our murine alloimmunization model is KEL-specific immunoglobulins. It is possible that useful information could have been obtained had KEL-specific antibody-secreting cells or antigen-specific T or B cells been able to be evaluated, but these studies are difficult with the tools currently available.
In sum, bortezomib decreased but did not eliminate primary alloantibody responses to transfused murine RBCs expressing the KEL glycoprotein. To the extent that these findings are generalizable to other RBC antigens and to humans, bortezomib monotherapy is unlikely to be of significant clinical benefit in a transfusion setting, where complete prevention of alloimmunization is desirable. A better understanding of transfusion-associated alloimmunization to RBC antigens, as well as the development of more optimal strategies to prevent or mitigate the formation of such alloantibodies, would benefit patients in transfusion and pregnancy settings alike.
